plus daily administration of Lantus SoloStar (insulin glargine), a long-acting insulin. Results show that the immunogenicity, efficacy, and safety findings were comparable between the biosimilar and ...

Sanofi lost its appeals court bid to revive patents on its blockbuster Lantus SoloStar insulin injection pen in a victory for drugmaker Viatris Inc. A review board was correct to invalidate five ...

To encourage broad patient access to this important medicine, Mylan is offering Semglee at a wholesale acquisition cost (WAC) 1 of $147.98 per package of five (5) 3ml pens and $98.65 per 10ml vial, ...

were nearly US$1.64 billion for Lantus 100 Units/ml vial and approximately US$4.36 billion for Lantus SoloSTAR Pen. Mylan and Biocon Biologic’s insulin glargine has received regulatory approval in ...

The US Patent Office ruled in favour of Mylan for a total of four device patents on Sanofi’s Lantus SoloSTAR. Lantus SoloSTAR is the disposable injection pen version of the drug. The other version by ...

Sanofi had challenged that Mylan’s device for insulin glargine product Semglee infringed the company’s patents for Lantus SoloSTAR. The PTAB, however, found Sanofi’s claims unpatentable.

Mylan N.V. MYL and partner Biocon Ltd. obtained ... for Lantus 100 Units/mL Vial and approximately $4.33 billion for Lantus SoloSTAR Pen. The approval brings an affordable treatment option for ...

The opportunity for Mylan and Biocon (which bills itself ... in revenue from Lantus vials and $4.33 billion from the Lantus SoloSTAR Pen in the 12-month period that ended in April.

Mumbai, Jun 12 (UNI) Biocon and Mylan NV on Friday announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Semglee™ (insulin glargine injection), in ...

HERTFORDSHIRE, UK and PITTSBURGH, PA, USA and BENGALURU, India I June 11, 2020 I Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug ...

were approximately $1.68 billion for Lantus 100 Units/mL Vial and approximately $4.33 billion for Lantus SoloSTAR Pen. Mylan and Biocon Biologic's insulin glargine has received regulatory approval in ...